ALVO Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 22:00):
Our systems believe the stock currently is overvalued by -0.89% compare to its pairs and should correct downwards.

Stats
Tagesvolumen	166 670
Durchschnittsvolumen	182 962
Marktkapitalisierung	3.40B
EPS	$-0.820 ( Q1 \| 2024-03-31 )
Nächstes Ertragsdatum	( $-0.280 ) 2024-09-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.85 (Sector) 42.63 (Industry) 30.78
ATR14	$0.00700 (0.06%)

AERI 0.00%

ALVO 1.33%

ALVOW 6.79%

BDSI -0.09%

BFRIW -5.93%

CLVRW 0.00%

CYTHW -4.35%

ENDP 0.00%

GRVI 7.61%

HPCO 0.06%

INDV -1.59%

JUPWW -20.00%

LFCR -0.19%

LNDC -3.52%

LSDI -23.29%

PRFX -3.65%

PROCW 10.09%

QLI 6.82%

SBFMW 0.00%

SHOT 9.43%

SHPH 4.28%

Korrelation (AI algo v.1.1b): Overvalued: -0.89% $12.24 paired level. (Der Algorithmus verfolgt in Echtzeit die Änderungen der am stärksten korrelierten Aktien und gibt eine sofortige Aktualisierung)

Volumen Korrelation

Lang: 0.27 (neutral)

Kurz: 0.44 (neutral)

Signal:(77.508) Neutral

Alvotech Korrelation

10 Am meisten positiv korreliert
OZEM	1
NUVO	0.806

10 Am meisten negativ korreliert
BKHA	-0.981
RFAIU	-0.915
PSTR	-0.881
ERNZ	-0.854
BKHAR	-0.832
INDH	-0.831
IBAC	-0.822
AGMI	-0.811
LENZ	-0.807

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Alvotech Korrelation - Währung/Rohstoff

-0.27
( neutral )

0.26
( neutral )

0.00
( neutral )

-0.45
( neutral )

0.58
( weak )

-0.20
( neutral )

Alvotech Finanzdaten

Annual	2023
Umsatz:	$91.43M
Bruttogewinn:	$-69.42M (-75.93 %)
EPS:	$-2.43

FY	2023
Umsatz:	$91.43M
Bruttogewinn:	$-69.42M (-75.93 %)
EPS:	$-2.43

FY	2023
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$0

FY	2022
Umsatz:	$83.03M
Bruttogewinn:	$18.93M (22.80 %)
EPS:	$-2.60

Financial Reports:

No articles found.

Alvotech Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company\'s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn\'s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn\'s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.